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ABSTRACT: Mesoporous silica-coated hollow manganese oxide (HMnO@
mSiO2) nanoparticles were developed as a novel T1 magnetic resonance
imaging (MRI) contrast agent. We hypothesized that the mesoporous
structure of the nanoparticle shell enables optimal access of water molecules
to the magnetic core, and consequently, an eﬀective longitudinal (R1)
relaxation enhancement of water protons, which value was measured to be
0.99(mM
-1s
-1)at11.7T.Adipose-derivedmesenchymalstemcells(MSCs)
were eﬃciently labeled using electroporation, with much shorter T1 values as
compared to direct incubation without electroporation, which was also
evidenced by signal enhancement on T1-weighted MR images in vitro. Intracranial grafting of HMnO@mSiO2-labeled MSCs enabled
serial MR monitoring of cell transplants over 14 days. These novel nanoparticles may extend the arsenal of currently available
nanoparticle MR contrast agents by providing positive contrast on T1-weighted images at high magnetic ﬁeld strengths.
’INTRODUCTION
In recent years, the use of nanoparticles for biomedical imag-
ing has revolutionized the ability to monitor molecular and
cellular events in living organisms. Semiconductor nanoparticles
(quantumdots)havebeenappliedasﬂuorescenceprobesforcell
labeling in optical imaging.
1-3 Gold nanoparticles have been
investigatedinopticalimagingandasbiomedicalsensorsbecause
of their unique optical and electrical properties.
4,5 Magnetic
nanoparticles have also been used as contrast enhancement
agents for magnetic resonance imaging (MRI), and as
biosensors.
6-12 MRI is currently one of the most powerful and
widely used imaging modalities that provides high spatial resolu-
tion combined with excellent anatomical details.
13-15
In the past decade, superparamagnetic iron oxide nanoparti-
cles (SPIO) have become the preferred technique for MRI cell
tracking,
16-21 and have now entered the clinical arena.
22,23
SPIO-labeled cells have much shorter transverse (T2) relaxation
time and thus, produce hypointensities (dark regions) on T2/
T2*-weighted MR images, which presumably indicate the loca-
tion of the transplanted cells. Unfortunately, SPIO-labeled cells
cannot be distinguished from other hypointense regions, such as
hemorrhageandbloodclots,whicharecommoninmanylesions.
Therefore, alternativetrackingmethodsusing“positive”contrast
agents have been explored, i.e. gadolinium (Gd)-based com-
plexes that can generate hyperintense regions as a result of their
predominant eﬀects on the longitudinal (T1) relaxation time of
water protons in tissue.
24-30 Unfortunately, gadolinium-based
contrast agents are now associated with nephrogenic sys-
temic ﬁbrosis (NSF), which makes them less favorable agents,
31
in particular when being retained in cells without rapid clearance
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from the body. A diﬀerent approach to enhance MRI contrast is
to use manganese as a T1 relaxation agent. Manganese has been
mostly used in the form of MnCl2 to study the structure and
function of normal or diseased brain.
32-34 MnCl2 was used for
direct labeling of cells in vitro.
35 Mn has also been chelated and
conjugated to proteins to achieve a higher r1 relaxivity.
36
Relaxivity (r1, for longitudinal relaxation) describes the change
in the relaxation rates of the water protons in the presence of a
given contrast agent. Contrast agents with high r1 values enable
lower concentrations of the agent, and consequently, result in
higher sensitivity.
25,36 Alternatively, the longitudinal relaxation
can be improved by increasing the number of Mn atoms per
particlethatcanexchangewiththewaterprotons,asinthecaseof
nanoparticles. Indeed, manganese oxide (MnO) nanoparticles
have recently been explored as a new T1 MR contrast agent that
can delineate ﬁne anatomical features in mouse brain,
37 and to
track cells with positive contrast.
38 However, most of the
reported manganese oxide nanoparticles provide weak contrast,
and the duration of signal is too short for long-term in vivo MR
contrast enhancement.
37-39
Coating of nanoparticles can signiﬁcantly improve their
stability, biocompatibility, and relaxivity.
3,16,21,39 Silica has been
recognizedasagoodcandidateforacoatingmaterialbecauseitis
relatively biocompatible and resistant to biodegradation.
40-44 In
particular, mesoporous silica material is an excellent candidate
due to its stability in aqueous solution and high labeling eﬃ-
ciency.
45-53 Furthermore, mesoporous silica allows easy access
for water molecules to the magnetic center, which signiﬁcantly
improves the water proton relaxation.
54,55 In this study, we report
on a novel design of MnO nanoparticles that have a ‘hollow’ MnO
core structure and a coating consisting of mesoporous silica
(termed HMnO@mSiO2). The high surface area-to-volume ratio
and water accessibility through the pores allows for an eﬃcient T1
MRcontrastagent.Thiswasdemonstratedinvitroandinvivoafter
labeling of multipotent adipose-derived mesenchymal stem cells
(MSCs) with HMnO@mSiO2 nanoparticles.
’EXPERIMENTAL SECTION
Synthesis of HMnO@mSiO2 Nanoparticles. Mesoporous si-
lica-coated MnO nanoparticles were prepared using the following pro-
cedure. First, uniformly sized 15 nm MnO nanoparticles were synthe-
sized by the thermal decomposition of Mn-oleate complex.
56 The
resulting MnO nanoparticles stabilized with oleic acid were dispersed
in chloroform at a concentration of 10.8 mg Mn/mL, as measured by
inductivelycoupledplasmaatomicemissionspectroscopy(ICP-AES).A
typical mesoporous silica coating onto MnO nanoparticles (MnO@
mSiO2) was performed using a sol-gel reaction of tetraethyl orthosi-
licate (TEOS) in an aqueous solution containing cetyltrimethylammo-
nium bromide (CTAB) and MnO nanoparticles stabilized with oleic
acid.
49 First, 600 μL of MnO nanoparticles in chloroform was poured
into 5 mL of 0.05 M aqueous CTAB solution and the resulting solution
was stirred for 1 h. Forming an oil-in-water microemulsion, the mixture
was heated up to 60  C and maintained at that temperature for 20 min
under stirring in order to evaporate the chloroform. The transparent
resulting solution of MnO/CTAB was added to a mixture of 25 mL of
waterand1.8mLof2MNaOHsolution,andthemixturewasheated.At
approximately 70  C under stirring, 0.3 mL of TEOS and 1.8 mL of
ethylacetate were added to the reaction solution in sequence. The
reaction was continued for 12 h at approximately 70  C. The washing
steps for MnO@mSiO2 nanoparticles with ethanol were performed to
remove unreacted species, and then the nanoparticles were redispersed
in 5 mL of ethanol.
For the hollow core structure of mesoporous silica-coated MnO
nanoparticles, an etching process was performed: 100 μL of mild
hydrochloric acid solution (4%) (pH ≈ 2.4) was added to the
dispersion followed by stirring for 1 h at 70  C. Acid-etched
MnO@mSiO2 nanoparticles were then dispersed in 5 mL ethanol.
After washing with ethanol two more times, nanoparticles were
redispersed in distilled water. After ﬁltration through a 450 nm
( p o r es i z e )c e l l u l o s ea c e t a t eﬁlter, HMnO@mSiO2 nanoparticles
were ﬁnally redispersed in phosphate buﬀered saline (PBS) (10 mM
phosphate, 138 mM NaCl, pH = 7.4) solution.
Relaxivity Measurements. MRI of phantoms was performed
using an 11.7 T Bruker Avance system equipped with a 15 mm birdcage
RF coil. T1 and T2 relaxation times were measured using a modified
multiecho spin echo (MSME) protocol.
38 Typical settings for T1 mea-
surements were as follows: 64   64 matrix size; echo time (TE) =
6.4ms;andarepetitiontime(TR)seriesof0.2,0.4,0.8,1,1.5,3,4,6,and
10s;and2averagespermeasurement.ForT2measurements,theparam-
eters were 128   128 matrix; 3000 ms repetition time; echo time
series of 6.4, 12.8, 19.2, 25.6, 32.0, 38.4, 44.8, 51.2, 57.6, 64.0, 70.4, and
76.8 ms; and 2 averages per measurement. Data processing was
performed using Matlab (Mathworks, Natick, MA).
Cell Labeling and Phantom Preparation. Electroporation
was used to label cells with HMnO@mSiO2 nanoparticles. Mouse
MSCs were cultured in 80 cm
2 flasks overnight to 80-90% confluence.
On the next day, cells were suspended using trypsin-ethylene diamine
tetraacetic acid (EDTA), washed with PBS, and counted. Cells were
resuspended and transferred to sterile 0.4 cm gap electroporation
cuvettes (Gene Pulser; Bio-Rad). Each cuvette contained 2   10
6 cells
suspended in580μL.Nanoparticles dispersed inPBSwereaddedto the
cuvette with a final volumeof 700 μL. Cuvettes were kept onicefor one
min, and cells were electroporated using a BTX electroporation system
(ECM830; Harvard Apparatus). The following electroporation condi-
tionswereused: pulsestrength=100V;Npulses=5;pulseduration=5ms;
and pulse interval = 100 ms. After 30 s,cells were transferred to ice for 2 min,
suspendedinculturemedium,transferredtosix-wellplates.At24hfollowing
electroporation, cells were washed twice with PBS, harvested using trypsin-
EDTA,andcounted.Forgelatinphantoms,2 10
6cellssuspendedin50μL
ofPBSweretransferredto0.5mLpolypropylenetubesandmixedwith50μL
of10%gelatininPBS.Thefinalcellconcentrationwas2 10
4cells/μLin5%
gelatin.
Cellular Imaging in Vitro. A solution of 2   10
6 MSCs sus-
pendedin580μLPBSwasmixedwith120μLHMnO@mSiO2(orPBS
as a control) and electroporated or incubated. MRI scans of in vitro
phantoms were obtained using a Bruker 9.4 T MRI scanner. T1
relaxation was measured using an MSME pulse sequence (for T1;
TE = 9 ms, and TR = 0.2, 0.3, 0.5, 0.8, 1, 1.5, 2, 4, 6, and 10 s). Data
processing was performed using Matlab (Mathworks, Natick, MA).
Cellular Imaging in Vivo. Animal experiments were performed
inaccordancewithaprotocolapprovedbyAnimalCareandUseCommittee
of the Johns Hopkins University School of Medicine. C15/BL6 male mice
(weighing 20 g) were anesthetized with ketamine/xylazine (100/15 mg per
kg), and positioned in a stereotaxic device (Stoelting, Wood Dale, IL,
U.S.A.). A small skin incision was made in the midline to expose the skull.
Using a motorized nanoinjector (Stoelting, Inc.) and 10 μL Hamilton
syringe (Hamilton, Reno, NV, U.S.A.) with an attached 33G needle, 1.0  
10
5 labeled or unlabeled MSCs were injected into the putamen of mice
(n=2),accordingtothefollowingcoordinatesfrombregma:anteroposterior
[AP] = 1.5 mm; mediolateral [ML] = 1.34 mm; and dorsoventral [DV] =
-3.5 mm. Cells were injected slowly over 4 min, and the needle was left in
placefor1minbeforebeingwithdrawn.Theincisionwasclosedwithsurgical
glue, and postoperative analgesia was provided with Ketofen (2 mg/kg) for
72 h.
SerialinvivoMRIscanswereperformedonaBruker9.4Thorizontal
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using an MSME pulse sequence. For T1 measurements, the following
parameters were used: TE = 10.5 ms; TR = 1.5 s; FOV = 2.1   2.1 cm;
and matrix size = 256   96.
’RESULTS AND DISCUSSION
Synthesis and Characterization of HMnO@mSiO2 Nano-
particles. Scheme 1 describes the synthesis of HMnO@mSiO2
nanoparticles and labeling of MSCs using electroporation.
Manganese oxide nanoparticles with a mean diameter of 15 nm,
stabilized with oleic acid, were synthesized by the thermal decom-
position of manganese oleate complex.
56 Then, mesoporous silica
shells werecoated with asilicasol-gelreactionoftetraethyl ortho-
silicate (TEOS) in aqueous solution containing cetyltrimethylam-
monium bromide (CTAB) and MnO nanoparticles under basic
conditions.
49 Hydrophobic MnO nanoparticles capped with oleic
acid were transferred to aqueous solution using CTAB, and the
subsequent formation of a mesoporous silica shell was achieved.
CTAB molecules were used not only as the stabilizing agent to
transfer hydrophobic nanoparticles to the aqueous phase, but also
as the organic structure-directing template to establish mesopores
on the silica shell. The creation of the hollow interior of the MnO
cores, along with template removal, was achieved by acid etching
and refluxing in ethanol solutions (pH ≈ 2.4). TEM revealed
discrete and uniformly sized HMnO@mSiO2 nanoparticles. The
average diameter of the particles was about 65 nm and the MnO
core size was 15 nm.The nanoparticles were all well-dispersed and
separated from one another. The mesoporous silica shell and
hollow MnO core structures can be clearly seen on the TEM
(Figure 1a) and HRTEM (Figure 1b) images. We also confirmed
the mesoporous structures of HMnO@mSiO2 nanoparticles using
N2 adsorption/desorption isotherms. The average pore diameter
calculated using the Barrett-Joiner-Halenda (BJH) method was
3.3 nm. The Brunauer-Emmett-Teller (BET) surface area and
pore volume of the HMnO@mSiO2 nanoparticles were measured
tobe181.3m
2g
-1and0.38cm
3g
-1(FigureS1,SupportingInfor-
mation), respectively. These BET results indicate that HMnO@
mSiO2 nanoparticles are highly porous and have large surface area,
which enables rapid access for water molecules to the manganese
corethroughthenanoporesoftheparticles.Inaddition,thehollow
interioroftheMnOcoresalsoenablesmoreMnionstobeexposed
to water molecules at the inner surface.
57 HMnO@mSiO2 nano-
particles that have a large surface area at the manganese center
resulting from these novel structures can be expected to have high
T1 relaxivities.
The MRI properties of the HMnO@mSiO2 nanoparticles in
water were characterized using an 11.7 T MR scanner. The
paramagnetic nanoparticles shortened the T1 of water protons
signiﬁcantly (Figure 1c). The molar relaxivity (eﬀectiveness as
contrast agent) was obtained by measuring the relaxation rate
with increasing concentrations of nanoparticles (Figure 1c),
and was calculated to be 0.99 mM
-1 s
-1 (Figure 1d). This
relaxivity is signiﬁcantlyhigher as comparedtothatmeasured for
MnO nanoparticles encapsulated with PEG-phospholipids
(MnO@PEG-phospholipid),
37,38 dense silica-coated MnO nano-
particles (MnO@dSiO2)
39 (Figure S2, Supporting Information),
and nonetched mesoporous silica-coated MnO nanoparticles
(MnO@mSiO2). Summarized in Table 1, the r1 values of
HMnO@mSiO2nanoparticles were 12.4, 9.0, and 1.5times higher
than those of the MnO@dSiO2, MnO@PEG-phospholipid, and
MnO@mSiO2 nanoparticles, respectively. These ﬁndings sug-
gest thatthemajorityoftheimprovementoverothernanoparticlesis
derived from the coating, consistent with our hypothesis that the
Figure 1. Characterization of HMnO@mSiO2 nanoparticles. (a) TEM
image. (b) HRTEM image of a single nanoparticle. (c) T1 map of
HMnO@mSiO2nanoparticles suspended in waterat 11.7 T.(d) Plot of
1/T1 versus Mn concentration. The slope indicates the speciﬁc relaxi-
vity (r1).
Scheme 1. Schematic Illustration of the Synthesis of HMnO@mSiO2 Nanoparticles and Labeling of MSCs2958 dx.doi.org/10.1021/ja1084095 |J. Am. Chem. Soc. 2011, 133, 2955–2961
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mesoporous shell allows better water exchange with the MnO core.
Water diﬀusion across mesoporous silica has been studied previously
using pulsed ﬁeld gradient (PFG) diﬀusion NMR.
58 It was shown
that water diﬀuses anisotropically inside mesoporous silica in com-
parison to isotropic diﬀusion in the surrounding environment, with
the fastest diﬀusion component occurring along the channels in the
mesoporous silica. The existence of nanopores allows water diﬀusion
to the manganese core leading to eﬃcient relaxation of water in the
vicinityofthenanoparticles.Infact,usingPFGNMRandmagicangle
spinning NMR, similar diﬀusion properties were shown for larger
moleculessuchaspentane,cyclohexane,n-dodecane,andaminoacids
such as alanine.
59 An additional improvement over MnO@mSiO2
(1.5 fold, see above) may be a result of the acidic etching, which
increases the surface area-to-volume ratio, and further increases the
exchangeofthewaterwithMn
2þions.Thisimprovementisinagree-
ment with previously reported relaxivity for hollow manganese oxide
nanoparticles.
57 Recent reports on other manganese-based nanopar-
ticlesdescribewiderangeofrelaxivity(r1)values.
39,57,60,61Itisdiﬃcult
to compare the relaxivities of those nanoparticles since the relaxivity
was measured at diﬀerent ﬁeld strengths (Table 1). When measured
at lowerﬁeld (1.5 T), the HMnO@mSiO2nanoparticles gave higher
r1butsimilarr2values(r1=1.72mM
-1s
-1,r2=11.30mM
-1s
-1)in
comparison to those measureda t1 1 . 7T .A se x p e c t e d ,t h er2/r1ratio
at lower ﬁe l di sl o w e r .T h ec l o s e rt h i sr a t i oi st o1 ,t h eb e t t e rt h e
nanoparticle will function as “positive” contrast agent. For example,
“Magnevist”(a commercial gadolinium complex) has an optimal r2/
r1 ratio of 1 (r1 =4 . 6m M
-1 s
-1, r2 =4 . 5m M
-1 s
-1)a t1 . 5T ,
62 in
comparison to 6.56 for HMnO@mSiO2 at the same ﬁeld strength.
When compared to manganese compounds
33,36 such as MnCl2 and
chelated manganese, the HMnO@mSiO2 nanoparticles have lower
relaxivity. Nevertheless, the nanoparticles were designed speciﬁcally
for cell labeling and tracking which is not possible with these
compounds, even if the relaxivity had to be compromised.
The X-ray diﬀraction (XRD) pattern (Figure S3, Supporting
Information)revealedpolycrystallinepropertiesoftheHMnO@
mSiO2 nanoparticles, consisting mainly of tetragonal Mn3O4
phaseandsmallfractionofcubicMnOphase.Theexistenceofan
amorphous silica shell also contributes to the broad peaks of the
patterns. In particular, it was found that the crystallinity of the
nanoparticle was decreased after the acid etching. The dissolu-
tion of the cubic MnO phase from the core part was also
examined. After acid etching, HMnO@mSiO2 nanoparticles
were mainly composed of the tetragonal Mn3O4 phase.
HMnO@mSiO2 nanoparticles are stable in water and PBS
solution for over a month. The hydrodynamic diameter of
HMnO@mSiO2 nanoparticles in PBS solution was measured
tobe86nmusingDynamicLightScattering(FigureS4,Support-
ingInformation).Thisdemonstratesthatnanoparticlesarestable
in PBS and do not form aggregates, which is desirable for its
use as intracellular labeling agent. This good colloidal stability of
the HMnO@mSiO2 nanoparticles results from the negative charge
of the silica surface. As shown by zeta potential (ζ)m e a s u r e m e n t s
(Figure S5, Supporting Information), the surface potential of the
HMnO@mSiO2 nanoparticles was -3 0 . 4 3( m V )i nP B S( 1 0m M
phosphate, 138 mM NaCl, pH = 7.4) solution.
Cellular Uptake and in Vitro MRI. In order to assess the
feasibility of HMnO@mSiO2 nanoparticles for cell labeling, we
initiallyevaluatedthecellularuptakeinvitro.Inthisstudy,wehave
chosen to use multipotent mesenchymal stem cells (MSCs),
which possess the ability to migrate to sites of tissue injury, have
manypossibletherapeuticapplications,includingthereplacement
of damaged tissue and the treatment of cancer.
63-65 Successful
clinicaltranslationfortheapplicationofMSCsrequiresanimaging
modality that noninvasively permits their visualization and locali-
zation in a living organism. Mouse adipose-derived MSCs were
labeled using either electroporation or a simple incubation
approach. Electroporation uses an electrical pulse to induce a
change in the electrochemical permeability of the cell membrane
and enables efficient intracytoplasmic labeling of cells.
66 This
approachiscommonlyusedfortransferringDNAandchemother-
apeutic drugs into cells, and was recently applied to cell labeling
with superparamagnetic iron oxide nanoparticles (SPIO)
67 and
MnOnanoparticles.
38Wehypothesizedthatelectroporationcould
also be efficiently used for cell labeling with HMnO@mSiO2
nanoparticles.Sincethecellmembraneisnegativelycharged,
68the
negativechargeofthenanoparticlewouldresultinrepulsionofthe
nanoparticles by the cell membrane, and thus, uptake would be
hampered. However, with electroporation, negatively charged
HMnO@mSiO2 nanoparticles can be effectively introduced into
cells without using other transfection agents, such as cationic,
positively charged molecules.
69
Figure 2a shows a T1-weighted MR image of tubes containing
MSCs electroporated with diﬀerent concentrations of HMnO@
mSiO2 nanoparticles suspended in 5% gelatin. The higher the
nanoparticle concentration used for labeling, the brighter the tube
appearedontheimage.Figure2bdemonstratesthatelectroporation
Table 1. Relaxivity Data of Manganese Oxide-Based Nanoparticles (per Mn)
nanoparticles
a r1 (mM
-1 s
-1) r2 (mM
-1 s
-1) r2/r1 ﬁeld (T) ref
HMnO@mSiO2 0.99 11.02 11.13 11.7 this paper
MnO@PEG-phospholipid 0.11 6.16 56 11.7 this paper
MnO@mSiO2 0.65 9.50 14.61 11.7 this paper
MnO@dSiO2 0.08 2.27 28.37 11.7 this paper
HMnO@mSiO2 1.72 11.30 6.56 1.5 this paper
WMON 0.21 1.49 7.09 3 57
HMON 1.42 7.74 5.45 3 57
Mn-NMOFs 4.0 112.8 28.2 9.4 60
Mn3O4@SiO2(RBITC) 0.47 N/A 3.0 39
HAS-MNOP 1.97 N/A 7.0 61
aNanoparticle annotations: HMnO@mSiO2 - mesoporous silica-coated, hollow MnO nanoparticles. MnO@PEG-phospholipid - MnO nanoparticles
encapsulated with PEG-phospholipid. MnO@mSiO2 - nonetched mesoporous silica-coated MnO nanoparticles. MnO@dSiO2 - dense silica-coated
MnO nanoparticles. WMON - water-dispersible manganese oxide nanoparticles. HMON - hollow manganese oxide nanoparticles. Mn-NMOFs -
manganese-containing nanoscale metal-organicframeworks (NMOFs). HAS-MNOP-human serum albumin-coated manganeseoxide nanoparticles.2959 dx.doi.org/10.1021/ja1084095 |J. Am. Chem. Soc. 2011, 133, 2955–2961
Journal of the American Chemical Society ARTICLE
with nanoparticles shortens T1 much more eﬃciently than
direct incubation of the cells with the nanoparticles. Figure 2c
showsthelinearcorrelationbetweentherelaxationrate(R1=1/T1)
and the concentration of nanoparticles that was used to label the
cells, both by electroporation (R
2= 0.994) and by incubation (R
2=
0.989). At higher nanoparticle concentration, the electroporation is
much more eﬃcient than incubation. For these samples, the
manganese ion content was measured using ICP measurement.
TheMnconcentrationwas9.0μgMn/mL(=0.35pgMn/cell)and
1.8 μg Mn/mL (= 0.09 pg Mn/cell) for phantom of MSCs labeled
with electroporation and incubation, respectively. These ﬁndings
indicate that 26.23% and 5.24% of the added nanoparticles were
taken up by MSCs using electroporation and incubation, respec-
tively. Next, both cellular labeling using electroporation and simple
incubation were investigated using nanoparticles conjugated with
rhodamine B isothiocyanate (RITC) (Figure 3). This ﬂuorescent
organic dye could be easily conjugated to the silica surface using
simplesilaneconjugationchemistry,aspreviouslyreported.
42,49,70,71
For the same nanoparticle concentration, MSCs labeled
with electroporation (Figure 3a) showed a higher uptake of
nanoparticles than MSCs labeled with incubation (Figure 3b).
There was also a clear concentration-dependent cellular uptake
of the nanoparticles. As was previously shown, compounds that
were introduced into the cells via incubation are more likely to
accumulate in endosomes, while with electroporation the com-
pounds are freely distributed within the cytoplasm. This may
also explain in part the lower relaxivity observed for cells incubated
with the particles in comparison to electroporation, since with
incubation the particles are in conﬁned region (endosome) and
have restricted exchange with water in contrast to electroporated
nanoparticles.
72
Cell Viability and Differentiation of Labeled MSCs. To
evaluate the possible cytotoxic effects of the HMnO@mSiO2
nanoparticles on MSCs, cell viability was assessed with the MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) assay. As shown in Figure S6,
high cell viability (more than 75%) was still attained at 24 h after
electroporation with HMnO@mSiO2 nanoparticles at a concen-
tration of 68.6 μg Mn/mL. The effect of electroporation with
HMnO@mSiO2 nanoparticles on the differentiation of adipose-
derived MSCs was also studied. It was found that MSCs retained
the ability to differentiate into adipocytes; however, differentiation
into an osteogenic phenotype could not be induced (Figure S7,
Supporting Information). These findings, taken together, indicate
that HMnO@mSiO2 nanoparticles by electroporation have a
minimal impact on cell viability, but its effect on cell differentiation
should be carefully evaluated for each specific application. In this
respect, it is important to note that while SPIOs were reported to
inhibit chondrogenesis,
73 SPIO-cell tracking clinical studies have
nevertheless been initiated.
22
In Vivo MR Imaging. In order to study the feasibility of
HMnO@mSiO2 nanoparticles for long-term in vivo cell
tracking, the fate of transplanted, labeled MSCs was serially
monitoredwithMRI.InmicetransplantedwithunlabeledMSCs,
no hyperintensity could be detected (red arrow, Figure 4a).
However, in mice transplanted with HMnO@mSiO2-labeled
MSCs,ahyperintenseregionwasobservedatthetransplantation
site (green arrows, Figure 4b). Serial imaging over 14 days
demonstrated that the nanoparticles were stable enough to
produce sustained contrast in vivo and, therefore, are suitable
for monitoring noninvasively the fate of transplanted cells.
The current HMnO@mSiO2 nanoparticles can be further
applied to MRI contrast agents for detecting tumors when
conjugated with antibodies
37 or RGD peptides
60 that can be
targeted directly to cancer cells or to the tumor vasculature,
respectively. Furthermore, stem cells labeled with the
HMnO@mSiO2 nanoparticles can assist in detecting tumors
becausestemcellstendtomigrateintotumorsites.
74,75Andmost
importantly, such stem cells can be engineered to perform an
antitumor activity.
Figure 2. (a) T1-weighted MR image of adipose derived MSCs suspended in 5% gelatin. The cells in each tube were electroporated with HMnO@mSiO2
nanoparticles (0-34.3 μg Mn/mL). (b) Normalized MRI signal intensity of cells electroporated with nanoparticles (34.3 μgM n / m L )( b), incubatedwith
nanoparticles (34.3 μgM n / m L )( 0), or electroporated without nanoparticles (Δ). (c) The R1 relaxation rate plotted as a function of the nanoparticle
concentration used for labeling the cells (electroporation (b), incubation (0)).
Figure 3. Fluorescence microscopy images of RITC-HMnO@mSiO2-
labeledMSCs,counterstained withHoechst33342.Using(a) electropora-
tionor(b) simpleincubationwithnanoparticles(0,11.4,and34.3μgMn/
mL) (left to right). Cellular uptake of nanoparticles was dose-dependent.
Higher nanoparticle uptake was observed in electroporated MSCs.2960 dx.doi.org/10.1021/ja1084095 |J. Am. Chem. Soc. 2011, 133, 2955–2961
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’CONCLUSIONS
In summary, we have synthesized and characterized mesopor-
ous silica-coated hollow manganese oxide nanoparticles. These
HMnO@mSiO2 nanoparticles showed a signiﬁcantly higher r1
relaxivity over other existing manganese oxide nanoparticle-
based contrast agents. The porous coating, which enables water
exchange across the shell, combined with the large surface area-
to-volumeratioresultingfromthenovelstructureincreaseswater
accessibility to the manganese core and consequently provides
enhanced T1 contrast. These nanoparticles showed high cellular
uptake by adipose-derived MSCs, using electroporation, and
were detected with MRI both in vitro and intracranially in vivo
overaprolongedtimeperiod.Inlightoftheseﬁndings,HMnO@
mSiO2 nanoparticles have a great potential for MRI cell tracking
using positive contrast.
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